STOCK TITAN
  1. Home
  2. News
  3. SEEL

Seelos Therapeutics Inc - SEEL STOCK NEWS

Welcome to our dedicated news page for Seelos Therapeutics (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on Seelos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Seelos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Seelos Therapeutics's position in the market.

News
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
Rhea-AI Summary
Seelos Therapeutics has retained Canaccord Genuity to assist in its review of potential partnerships, collaborations, and similar opportunities. The company is focused on developing therapies for central nervous system disorders and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
partnership
-
News
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
Rhea-AI Summary
Seelos Therapeutics announces encouraging preclinical data for SLS-005, showing a 46% reduction in tau protein and an 18% reduction in NfL biomarker within six months. The company will present these findings at Neuroscience 2023. Top-line data from the SLS-005 Phase II/III trial in ALS is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
-
News
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
Rhea-AI Summary
Seelos Therapeutics announces securities purchase agreement for 15M shares of common stock and warrants, raising $4.5M
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.71%
Tags
offering
News
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
Rhea-AI Summary
Seelos Therapeutics announces positive results for SLS-002 in Phase II study for Acute Suicidal Ideation and Behavior in adults with Major Depressive Disorder (MDD). Early and persistent reductions in symptoms of depression and acute suicidality were observed. SLS-002 demonstrated clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile. MADRS results showed statistically significant change relative to placebo at 4 hours, 24 hours, and Day 16. MADRS Response Rate and Remission Rate were higher in the SLS-002 group compared to placebo. SLS-002 also showed a reduction in acute suicidality symptoms. The study did not meet the pre-defined primary endpoint but would have achieved statistical significance if fully enrolled. No deaths reported. SLS-002 has the potential to address the unmet need in treating ASIB in MDD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-69%
Tags
clinical trial
-
News
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.64%
Tags
earnings
-
News
Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
none
News
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences
-
News
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
earnings
-
News
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
conferences
News
Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
Stock SEEL logo
Seelos Therapeutics Inc

Nasdaq:SEEL

SEEL Rankings

N/A Ranked by Market Cap
#5248 Ranked by Stock Gains
N/A Ranked by Dividends

SEEL Stock Data

6.32M
13.40M
2%
21.66%
5.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About SEEL

seelos therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. the company's lead programs are sls-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; sls-005, a protein stabilizer for the treatment of sanfilippo syndrome; and sls-006, a partial dopamine agonist for the treatment of patients with parkinson's disease (pd). its preclinical programs include sls-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with pd; sls-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; sls-004 for the treatment of pd; sls-010, an oral histamine h3a receptor antagonist for narcolepsy a